Jeffrey Jarrett, MD
Pulmonary Disease · Lincoln, NENPI 1023026663
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.7%), consulting fees and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Sanofi at 57.2% of the total. 2025 is the largest year on record at $3,257, 6.6 times the $494 reported in 2019.
Across 114 payments — averaging $40.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$3K
- Sunovion Pharmaceuticals Inc.$245
- Grifols USA, LLC$203
- Jazz Pharmaceuticals Inc.$149
- Philips North America LLC$139
- Amgen$136
- plus $1K from 28 others
What the payments were for
- Consulting fees$2,10846%
- Travel & lodging$732%
- Food & beverage$2,28550%
- Education$1353%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 15 | $2,632 |
| Sunovion Pharmaceuticals Inc. | 14 | $245 |
| Grifols USA, LLC | 10 | $203 |
| Jazz Pharmaceuticals Inc. | 9 | $149 |
| Philips North America LLC | 3 | $139 |
| Amgen | 8 | $136 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Resmed Corp | 2 | $96 |
| Boehringer Ingelheim | 6 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $68 |
| Harmony Biosciences LLC | 3 | $59 |
| GSK | 4 | $59 |
| Merck | 3 | $56 |
| Verona Pharma, Inc. | 3 | $54 |
| Actelion Pharmaceuticals US, Inc. | 3 | $43 |
| Regeneron Healthcare Solutions, Inc. | 3 | $43 |
| Mylan Specialty L.p. | 3 | $43 |
| Abiomed | 1 | $38 |
| Tactile Systems Technology Inc | 1 | $35 |
| Insmed, Inc. | 2 | $34 |
| Baxter Healthcare | 2 | $34 |
| Bayer | 2 | $31 |
| 3b Medical, Inc. | 2 | $30 |
| Genentech USA, Inc. | 2 | $26 |
| United Therapeutics Corporation | 1 | $20 |
| CSL Behring | 1 | $18 |
| AbbVie | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $13 |
| Novartis | 1 | $12 |
| Veran Medical Technologies, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SRC Und$113
How this compares
$4,601 in reported general payments places this provider in the 65th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 63 | $1,506,312 |
| OpsumitMacitentan | 48 | $600,070 |
| Ambrisentan | 114 | $442,881 |
| LetairisAmbrisentan | 12 | $259,407 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 187 | $141,260 |
| OfevNintedanib Esylate | 11 | $132,923 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 90 | $55,940 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 64 | $40,900 |
| Tadalafil | 39 | $32,017 |
| Spiriva RespimatTiotropium Bromide | 38 | $25,147 |
| Breo ElliptaFluticasone/Vilanterol | 57 | $22,442 |
| SymbicortBudesonide/Formoterol Fumarate | 67 | $20,854 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $17,866 |
| XareltoRivaroxaban | 33 | $12,488 |
| Tiotropium Bromide | 16 | $8,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $43 | $2,106,382111 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $96 | $214,010139 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $59 | $189,139293 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $14 | $61,755131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Lincoln
- Ryan MartinLincoln$600K
- Douglas FiedlerLincoln$23K
- Kevin ReichmuthLincoln$22K
- Harvey HopkinsLincoln$18K
- William JohnsonLincoln$18K
- Matthew MaslonkaLincoln$14K
- Jakeb RiggleLincoln$13K
- Jonathan SpencerLincoln$9K
- Louis VioliLincoln$6K
- Sean BarryLincoln$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.